These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23101586)

  • 1. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.
    Park JH; Liu Y; Lemmon MA; Radhakrishnan R
    Biochem J; 2012 Dec; 448(3):417-23. PubMed ID: 23101586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
    Wood ER; Truesdale AT; McDonald OB; Yuan D; Hassell A; Dickerson SH; Ellis B; Pennisi C; Horne E; Lackey K; Alligood KJ; Rusnak DW; Gilmer TM; Shewchuk L
    Cancer Res; 2004 Sep; 64(18):6652-9. PubMed ID: 15374980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
    Furuyama K; Harada T; Iwama E; Shiraishi Y; Okamura K; Ijichi K; Fujii A; Ota K; Wang S; Li H; Takayama K; Giaccone G; Nakanishi Y
    Cancer Sci; 2013 May; 104(5):584-9. PubMed ID: 23387505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
    Ji H; Zhao X; Yuza Y; Shimamura T; Li D; Protopopov A; Jung BL; McNamara K; Xia H; Glatt KA; Thomas RK; Sasaki H; Horner JW; Eck M; Mitchell A; Sun Y; Al-Hashem R; Bronson RT; Rabindran SK; Discafani CM; Maher E; Shapiro GI; Meyerson M; Wong KK
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7817-22. PubMed ID: 16672372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors.
    Macdonald-Obermann JL; Pike LJ
    J Biol Chem; 2018 Aug; 293(35):13401-13414. PubMed ID: 29997256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
    Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
    Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
    Zerbe LK; Dwyer-Nield LD; Fritz JM; Redente EF; Shroyer RJ; Conklin E; Kane S; Tucker C; Eckhardt SG; Gustafson DL; Iwata KK; Malkinson AM
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):605-20. PubMed ID: 18030469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
    Vivanco I; Robins HI; Rohle D; Campos C; Grommes C; Nghiemphu PL; Kubek S; Oldrini B; Chheda MG; Yannuzzi N; Tao H; Zhu S; Iwanami A; Kuga D; Dang J; Pedraza A; Brennan CW; Heguy A; Liau LM; Lieberman F; Yung WK; Gilbert MR; Reardon DA; Drappatz J; Wen PY; Lamborn KR; Chang SM; Prados MD; Fine HA; Horvath S; Wu N; Lassman AB; DeAngelis LM; Yong WH; Kuhn JG; Mischel PS; Mehta MP; Cloughesy TF; Mellinghoff IK
    Cancer Discov; 2012 May; 2(5):458-71. PubMed ID: 22588883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
    Xu Y; Liu H; Chen J; Zhou Q
    Cancer Biol Ther; 2010 Apr; 9(8):572-82. PubMed ID: 20404520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    Minnelli C; Laudadio E; Mobbili G; Galeazzi R
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.
    Becker C; Öcal S; Nguyen HD; Phan T; Keul M; Simard JR; Rauh D
    Chembiochem; 2016 Jun; 17(11):990-4. PubMed ID: 26991964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occupy EGFR.
    Park JH; Lemmon MA
    Cancer Discov; 2012 May; 2(5):398-400. PubMed ID: 22588876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
    Gazdar AF
    Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
    Augustin A; Lamerz J; Meistermann H; Golling S; Scheiblich S; Hermann JC; Duchateau-Nguyen G; Tzouros M; Avila DW; Langen H; Essioux L; Klughammer B
    Mol Cancer Ther; 2013 Apr; 12(4):520-9. PubMed ID: 23371860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
    Lu C; Mi LZ; Schürpf T; Walz T; Springer TA
    J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
    Takada Y; Matsuo K
    Keio J Med; 2012; 61(4):120-7. PubMed ID: 23324306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
    Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
    J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.